Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Perspectives on Clinical Trials in Spinal Muscular Atrophy

Kathryn J. Swoboda, MD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, swoboda{at}genetics.utah.edu

John T. Kissel, MD

Department of Neurology, Ohio State University School of Medicine, Columbus, Ohio

Thomas O. Crawford, MD

Departments of Neurology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Mark B. Bromberg, MD, PhD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah

Gyula Acsadi, MD, PhD

Departments of Neurology and Pediatrics, Wayne State University School of Medicine, Detroit, Michigan

Guy D'Anjou, MD

Division of Pediatric Neurology, Hôpital Sainte-Justine Montréal, Montréal, Québec, Canada

Kristin J. Krosschell, MA, PT

Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Sandra P. Reyna, MD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah

Mary K. Schroth, MD

Department of Pediatrics, The University of Wisconsin School of Medicine, Madison, Wisconsin

Charles B. Scott, PhD

Louise R. Simard, PhD

Departments of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada

Spinal muscular atrophy is one of the most heterogeneous of the single-gene neuromuscular disorders. The broad spectrum of severity, with onset from the prenatal period to adulthood, presents unique challenges in the design and implementation of clinical trials. The clinical classification of subjects into severe (type 1), intermediate (type 2), and mild (type 3) subtypes has proved useful both in enhancing communication among clinicians internationally and in forging the collaborative development of outcome measures for clinical trials. Ideally, clinical trial design in spinal muscular atrophy must take into account the spinal muscular atrophy type, patient age, severity-of-affection status, nature of the therapeutic approach, timing of the proposed intervention relative to disease progression, and relative homogeneity of the cohort to be studied. Following is an overview of the challenges and opportunities, current and future therapeutic strategies, and progress to date in clinical trials in spinal muscular atrophy.

Key Words: spinal muscular atrophy • clinical trials • histone deacetylase inhibitors

References

  • Workshop Report. International Spinal Muscular Atrophy Collaboration. Neuromuscul Disord. 1991;1:81.[CrossRef]
  • Bertini E., Burghes A., Bushby K., et al. Outcome Measures and Treatment of Spinal Muscular Atrophy. Presented at the 134th ENMC International Workshop, Naarden, The Netherlands, Feb 11-13, 2005. Neuromuscul Disord. 2005;11:802-816.
  • Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20-26.[Web of Science][Medline] [Order article via Infotrieve]
  • Monani UR, Sendtner M., Coovert DD, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000;9:333-339.[Abstract/Free Full Text]
  • Swoboda KJ, Prior TW, Scott CE, et al. Natural history of distal motor neuron denervation in spinal muscular atrophy, and association of SMN2 copy number with functional outcomes. Ann Neurol. 2005;57:704-712.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Krosschell KJ, Muczulski JA, Crawford TO, et al.. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006; 16:417-426.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zerres K., Rudnik-Schoneborn, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and II spinal muscular atrophy): 569 patients. J Neurol Sci. 1997;146:67-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-9813.[Abstract/Free Full Text]
  • Echaniz-Laguna A., Miniou P., Bartholdi D., Melki J. The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am J Hum Genet. 1999;64:1365-1370.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Monani UR, McPherson JD, Burghes AH Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT). Biochim Biophys Acta. 1999;1445:330-336.[Medline] [Order article via Infotrieve]
  • Kernochan LE, Russo ML, Woodling NS, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet. 2005;14:1171-1182.[Abstract/Free Full Text]
  • Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647-654.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481-2489.[Abstract/Free Full Text]
  • Andreassi C., Angelozzi C., Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004;12:59-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hahnen E., Eyupoglu IY, Brichta L., et al. In vitro and ex vivo evaluation of second generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem. 2006;98:193-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Riessland M., Brichta L., Hahnen E., Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet. 2006;120:101-110.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Butchbach M., Le TT, Burghes Ahm. Protective effects of butyrate analogues and prodrugs on a mouse model for spinal muscular atrophy [abstract]. 34th Annual Society of Neuroscience Meeting, San Diego, 2004;23:27.
  • Ryu H., Smith K., Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93:1087-98. Erratum: 2006;96:908.[CrossRef][Web of Science]
  • Brahe C., Vitali T., Tiziano FD, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2005;13:256-259.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mercuri E., et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007;68:51-55.[Abstract/Free Full Text]
  • Grzeschik SM, Ganta M., Prior TW, et al. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol. 2005;58:194-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007;17:659-61.
  • Jarecki J., Chen X., Bernardino A., et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet. 2005;14:2003-2018.[Abstract/Free Full Text]
  • Andreassi C., Jarecki J., Zhou J., et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet. 2001;10:2841-2849.[Abstract/Free Full Text]
  • Cartegni L., Krainer AR Correction of disease-associated exon skipping by synthetic exon- specific activators. Nat Struct Biol. 2003;10:120-125.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Skordis LA, Dunckley MG, Yue B., et al. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A. 2003;100:4114-4119.[Abstract/Free Full Text]
  • Lunn MR, Root DE, Martino AM, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol. 2004;11:1489-1493.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolstencroft EC, Mattis V., Bajer AA, et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet. 2005;14:1199-1210.[Abstract/Free Full Text]
  • Chang HC, Hung WC, Chuang YJ, Jong YJ Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int. 2004;45:1107-1112.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haddad H., Cifuentes-Diaz C., Miroglio A., et al. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve. 2003;28:432-437.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Russman BS, Iannaccone ST, Samaha FJ A phase I trial of riluzole in spinal muscular atrophy. Arch Neurol. 2003;60: 1601-1603.[Abstract/Free Full Text]
  • Miller RG, Moore DH, Dronsky V., et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci. 2001;191:127-131.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Merlini L., Solari A., Vita G., et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003;18:537-541.[Abstract/Free Full Text]
  • Lesbordes JC, Cifuentes-Diaz C., Miroglio A., et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12:1233-1239.[Abstract/Free Full Text]
  • Kinali M., Mercuri E., Main M., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002;59:609-10.[Abstract/Free Full Text]
  • Kissel JT, McDermott MP, Mendell JR, et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001;57:1434-1440.[Abstract/Free Full Text]
  • Holzbaur EL, Howland DS, Weber N., et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis. 2006;23:697-707.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Azzouz M., Le T., Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest. 2004;114:1726-1731.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Baughan T., Shababi M., Coady TH, et al. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther. 2006;14:54-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nayak MS, Kim Y-S., Goldman M., et al. Cellular therapies in motor neuron diseases. Biochim Biophys Acta. 2006;1762:1128-1138.[Medline] [Order article via Infotrieve]
  • Harper JM, Krishnan C., Darman JS, et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuroninjured adult rats. Proc Natl Acad Sci U S A. 2004;101:7123-7128.[Abstract/Free Full Text]
  • Grondard C., Biondi O., Armand AS, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci. 2005;25:7615-7622.[Abstract/Free Full Text]
  • Kirkinezos IG, Hernandez D., Bradley WG, Moraes CT Regular exercise is beneficial to a mouse model amyotrophic lateral sclerosis. Ann Neurol. 2001; 53:804-807.

Journal of Child Neurology, Vol. 22, No. 8, 957-966 (2007)
DOI: 10.1177/0883073807305665
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
R. A. Brumback
Child Neurologists Should Be Interested In Brain Tumors!
J Child Neurol, November 1, 2009; 24(11): 1338 - 1340.
[PDF]

Home page
 NeurologyHome page
F. Deymeer, P. Serdaroglu, Y. Parman, and M. Poda
Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude
Neurology, August 26, 2008; 71(9): 644 - 649.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?